MX2020011449A - Oxiesteroles y metodos de uso de los mismos. - Google Patents

Oxiesteroles y metodos de uso de los mismos.

Info

Publication number
MX2020011449A
MX2020011449A MX2020011449A MX2020011449A MX2020011449A MX 2020011449 A MX2020011449 A MX 2020011449A MX 2020011449 A MX2020011449 A MX 2020011449A MX 2020011449 A MX2020011449 A MX 2020011449A MX 2020011449 A MX2020011449 A MX 2020011449A
Authority
MX
Mexico
Prior art keywords
sup
oxysterols
methods
compounds
formula
Prior art date
Application number
MX2020011449A
Other languages
English (en)
Inventor
Francesco G Salituro
Albert Jean Robichaud
Botella Gabriel Martinez
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2020011449A publication Critical patent/MX2020011449A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Abstract

Se proporcionan compuestos de acuerdo con la Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de la misma, y composiciones farmacéuticas de la misma; en donde R1, R2, R3, R6, R7, R8, y n son como se definen en la presente. Los compuestos de la presente invención se contemplan útiles para la prevención y tratamiento de una variedad de afecciones.
MX2020011449A 2015-07-06 2016-07-06 Oxiesteroles y metodos de uso de los mismos. MX2020011449A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189048P 2015-07-06 2015-07-06
US201662280394P 2016-01-19 2016-01-19
PCT/US2016/041168 WO2017007836A1 (en) 2015-07-06 2016-07-06 Oxysterols and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2020011449A true MX2020011449A (es) 2022-02-28

Family

ID=57686105

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000282A MX2018000282A (es) 2015-07-06 2016-07-06 Oxiesteroles y metodos de uso de los mismos.
MX2020011449A MX2020011449A (es) 2015-07-06 2016-07-06 Oxiesteroles y metodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000282A MX2018000282A (es) 2015-07-06 2016-07-06 Oxiesteroles y metodos de uso de los mismos.

Country Status (28)

Country Link
US (3) US10201550B2 (es)
EP (2) EP3828194A1 (es)
JP (3) JP2018519351A (es)
KR (1) KR20180026743A (es)
CN (2) CN108135912B (es)
AU (3) AU2016289967B2 (es)
BR (3) BR122023021450A2 (es)
CA (1) CA2991214A1 (es)
CO (1) CO2018000660A2 (es)
CY (1) CY1124496T1 (es)
DK (1) DK3319611T3 (es)
ES (1) ES2865258T3 (es)
HR (1) HRP20210526T8 (es)
HU (1) HUE053778T2 (es)
IL (2) IL256710B2 (es)
LT (1) LT3319611T (es)
MA (2) MA42410B1 (es)
MD (1) MD3319611T2 (es)
MX (2) MX2018000282A (es)
PE (1) PE20180483A1 (es)
PH (1) PH12018500065A1 (es)
PL (1) PL3319611T3 (es)
PT (1) PT3319611T (es)
RS (1) RS61718B1 (es)
RU (2) RU2744267C2 (es)
SG (1) SG10202010553XA (es)
SI (1) SI3319611T1 (es)
WO (1) WO2017007836A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4245369A3 (en) 2011-09-08 2023-11-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
RS62235B1 (sr) 2013-03-13 2021-09-30 Sage Therapeutics Inc Neuroaktivni steroidi
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR20180026743A (ko) 2015-07-06 2018-03-13 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
DK3319612T3 (da) 2015-07-06 2021-08-23 Sage Therapeutics Inc Oxysteroler og fremgansmåder til anvendelse derfor
LT3436022T (lt) * 2016-04-01 2022-06-27 Sage Therapeutics, Inc. Oksisteroliai ir jų panaudojimo būdai
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PT3481846T (pt) 2016-07-07 2021-08-13 Sage Therapeutics Inc 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
BR112019006365A2 (pt) 2016-09-30 2019-08-06 Sage Therapeutics Inc oxisteróis substituídos c7 e métodos de utilização dos mesmos
MX2019004578A (es) 2016-10-18 2019-10-09 Sage Therapeutics Inc Oxisteroles y metodos de uso de los mismos.
CN115322238A (zh) 2016-10-18 2022-11-11 萨奇治疗股份有限公司 氧甾醇及其使用方法
CA3050001A1 (en) 2017-01-13 2018-07-19 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CA3223179A1 (en) 2021-06-11 2022-12-15 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
CN113667734B (zh) * 2021-07-16 2022-05-24 四川大学华西医院 Shank3片段序列甲基化检测试剂在制备精神分裂症诊断试剂盒中的用途
WO2023028278A2 (en) * 2021-08-25 2023-03-02 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0701444B1 (en) 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE69535623T2 (de) 1994-02-14 2008-07-24 Euro-Celtique S.A. Androstane und Pregane zur allosterischen Modulation des GABA Rezeptors
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
PT837874E (pt) 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
US5841272A (en) 1995-12-20 1998-11-24 Sundstrand Corporation Frequency-insensitive current sensor
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
US6376530B1 (en) * 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
EP1450816A4 (en) 2001-11-08 2008-02-13 Univ Chicago METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION
AU2002360489A1 (en) 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
TWI329016B (en) 2002-03-27 2010-08-21 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
KR101130212B1 (ko) 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
GB0216621D0 (en) * 2002-07-17 2002-08-28 Imaging Res Solutions Ltd Imaging compounds
AU2003291074A1 (en) * 2002-11-22 2004-06-18 Merck & Co., Inc. 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as NR2B receptor antagonists
WO2004055201A2 (en) 2002-12-13 2004-07-01 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
NZ599643A (en) 2007-06-20 2013-11-29 Auspex Pharmaceuticals Inc Substituted N-aryl pyridinones as fibrotic inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
MX2010004682A (es) 2007-11-06 2010-05-19 Organon Nv Metodo de supresion de hormonas en humanos.
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
WO2009137843A2 (en) 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2459581A4 (en) 2009-07-29 2012-12-26 Univ Chicago LIVER X RECEPTOR AGONISTS
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en) * 2010-05-14 2010-06-30 Ge Healthcare Ltd Method of synthesis
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
US20150031655A1 (en) 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CA2874998A1 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
EP2736919A4 (en) 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
EP4245369A3 (en) * 2011-09-08 2023-11-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT2766380T (pt) 2011-10-14 2019-07-29 Sage Therapeutics Inc Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
EP2841067A4 (en) 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
WO2014028942A2 (en) 2012-08-17 2014-02-20 Trueex Group Llc Interoffice bank offered rate financial product and implementation
CN105026415B (zh) 2012-12-18 2019-02-01 华盛顿大学 神经活性的19-烷氧基-17-取代的甾族化合物、其前药以及利用所述化合物的治疗方法
CN105073119A (zh) 2013-01-23 2015-11-18 司菲埃拉制药私人有限公司 用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物
PE20151437A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
RS62235B1 (sr) 2013-03-13 2021-09-30 Sage Therapeutics Inc Neuroaktivni steroidi
WO2014160441A1 (en) * 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
US10016095B2 (en) * 2014-10-03 2018-07-10 Progressive International Corporation Salad spinner
EP3204011A4 (en) 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
DK3319612T3 (da) 2015-07-06 2021-08-23 Sage Therapeutics Inc Oxysteroler og fremgansmåder til anvendelse derfor
KR20180026743A (ko) 2015-07-06 2018-03-13 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
US11066437B2 (en) 2017-06-23 2021-07-20 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
AU2018364659A1 (en) 2017-11-10 2020-05-28 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders

Also Published As

Publication number Publication date
US20180200267A1 (en) 2018-07-19
RU2021100620A (ru) 2021-01-29
BR122023021450A2 (pt) 2023-12-26
HRP20210526T8 (hr) 2021-08-20
EP3319611B1 (en) 2021-01-20
CO2018000660A2 (es) 2018-07-10
CN108135912B (zh) 2021-07-02
MX2018000282A (es) 2018-03-08
US10201550B2 (en) 2019-02-12
CN113292623A (zh) 2021-08-24
PT3319611T (pt) 2021-04-22
LT3319611T (lt) 2021-05-10
AU2024200268A1 (en) 2024-02-01
AU2021218228A1 (en) 2021-09-09
SI3319611T1 (sl) 2021-08-31
MA55097A (fr) 2022-01-05
PE20180483A1 (es) 2018-03-07
ES2865258T3 (es) 2021-10-15
EP3319611A1 (en) 2018-05-16
SG10202010553XA (en) 2020-12-30
EP3319611A4 (en) 2019-03-06
HRP20210526T1 (hr) 2021-05-28
BR122021005552B1 (pt) 2024-01-02
US20190125764A1 (en) 2019-05-02
RS61718B1 (sr) 2021-05-31
PL3319611T3 (pl) 2021-07-12
EP3828194A1 (en) 2021-06-02
JP2021054864A (ja) 2021-04-08
JP2022120062A (ja) 2022-08-17
DK3319611T3 (da) 2021-04-12
MA42410A (fr) 2018-05-16
MA42410B1 (fr) 2021-04-30
PH12018500065A1 (en) 2018-07-09
BR112018000129B1 (pt) 2024-01-09
RU2018104278A3 (es) 2019-10-31
IL256710A (en) 2018-03-29
HUE053778T2 (hu) 2021-07-28
MD3319611T2 (ro) 2021-06-30
IL305404A (en) 2023-10-01
CA2991214A1 (en) 2017-01-12
BR112018000129A2 (pt) 2018-09-04
AU2016289967A1 (en) 2018-02-01
RU2744267C2 (ru) 2021-03-04
CN108135912A (zh) 2018-06-08
AU2021218228B2 (en) 2023-11-16
RU2018104278A (ru) 2019-08-06
JP2018519351A (ja) 2018-07-19
AU2016289967B2 (en) 2021-09-09
US10765685B2 (en) 2020-09-08
CY1124496T1 (el) 2022-07-22
WO2017007836A1 (en) 2017-01-12
IL256710B2 (en) 2024-01-01
US20210145848A1 (en) 2021-05-20
IL256710B1 (en) 2023-09-01
KR20180026743A (ko) 2018-03-13

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
TN2017000031A1 (en) Imidazopyridazine compounds
MX2020001157A (es) Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2015002755A3 (en) Compounds for the treatment of malaria
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
WO2015001541A3 (en) Pharmaceutical film composition
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.